|
微核糖核酸-361-5p（miR-361-5p）已被报道在结直肠癌、胃癌、前列腺癌中有肿瘤抑制作用，但在宫颈癌中为致癌基因。既往缺乏关于miR-361-5p表达及其对乳腺癌确切预后作用的研究。 2016年7月，《胸部疾病杂志》第8卷第7期正式发表复旦大学附属肿瘤医院、复旦大学上海医学院、复旦大学生物医学研究院的研究报告，发现miR-361-5p表达阳性提示乳腺癌患者预后较好。 该研究采用组织微阵列miRNA探测原位杂交锁定核酸探针检测了375例乳腺癌组织的miR-361-5p表达，调查了miR-361-5p在乳腺癌中的表达水平及其潜在的预后价值。 结果发现，在375例乳腺癌组织中295例（78.7%）可见miR-361-5p染色阳性。 miR-361-5p表达阳性患者的临床结局显著优于miR-361-5p表达阴性患者，中位无病生存时间分别为95.52个月、82.33个月（P=0.002）。 此外，miR-361-5p对于三阴性乳腺癌患者无病生存的预后价值最为显著（P=0.004）。 这些结果表明，乳腺癌miR-361-5p表达是预后较好的独立预测指标之一。 J Thorac Dis. 2016 Jul;8(7):1772-9. Positive expression of miR-361-5p indicates better prognosis for breast cancer patients. Cao ZG, Huang YN, Yao L, Liu YR, Hu X, Hou YF, Shao ZM. Fudan University Shanghai Cancer Center, Shanghai, China; Shanghai Medical College, Fudan University, Shanghai, China; Institutes of Biomedical Science, Fudan University, Shanghai, China. BACKGROUND: MicroRNA-361-5p (miR-361-5p) has been reported to be tumor suppressor in colorectal, gastric and prostate cancer, but as an oncogene in cervical cancer. No previous research has focused on the expression of miR-361-5p and its exact prognostic role in breast cancer (BC). METHODS: In this study, a tissue microarray (TMA)-based miRNA detection in situ hybridization (ISH) with LNA probe was used to detect miR-361-5p expression in 375 BC tissue. The expression level of miR-361-5p in BC and its potential prognostic value was investigated. RESULTS: Positive miR-361-5p staining was observed in 78.7% (N=295; 78.7% positive, 21.3% negative) in the 375 cases. The clinical outcome of patients with positive miR-361-5p expression [median disease-free survival (DFS) time 95.52 months] was significantly better than that of patients (median DFS time 82.33 months) with negative miR-361-5p expression (P=0.002). Moreover, the prognostic value of miR-361-5p was most significant among patients with triple-negative breast cancer (TNBC) for DFS (P=0.004). CONCLUSIONS: These results indicated that miR-361-5p expression is an independent predictive factor for better prognosis in BC. KEYWORDS: MiR-361-5p; breast cancer (BC); in situ hybridization(ISH); prognosis PMID: 27499968 DOI: 10.21037/jtd.2016.06.29 |
|
|
